IL6 and plasma cell myeloma: With regards to cancerimmunotherapy, the blockade of IL-6 has been shown to reduce tumor growth in myelomamodels [39].Our data suggest that the use of CDK inhibitors may block production of IL-6 andtherefore be of benefit to myeloma patients.